Foreign pharmaceutical companies are still working on the domestic market, but they have become less to sell drugs. Import substitution makes itself felt?
This, in particular, is about the “MSD Pharmasyutikals” (this is a division of the foreign farm producer MSD in Russia).
Last year, the company decreased the revenue by 37%. The reason for this is the reduction of the product portfolio due to changes in market conditions, the correspondent of The Moscow Post reports with reference to “Kommersant”. RNC Pharma Development Director Nikolai Bespalov, whose words gives the publication, says that MSD last year supplied 29 drugs to Russia, although in 2022 the figure was significantly higher – 38. 
Sanctions or competition?
After the start of the special operation, some foreign companies announced that they were leaving the Russian market. Among them were representatives of the pharmaceutical industry. And this is despite the lack of restrictions in this industry.
MSD, reducing the portfolio, had to significantly reduce the staff of employees in the Russian Federation. In this connection, the weekend of the resettered weekend resulted in a solid amount.
According to Kommersant, the company removed medicines from the market that could not withstand competition with generics. A further decrease in the presence is not excluded?
The company re -registered part of the products produced and supplied to the Russian Federation to another structure.
Domestic pharmaceutical companies are probably a win in connection with the departure of foreign competitors. However, does the consumer benefit from this? If you look at the data of the Ministry of Health, it turns out that yes. According to information ministriesdomestic medicines are cheaper than foreign.
The situation was commented by the assistant to the head of the department, Alexei Kuznetsov.
He, in particular, said that domestic pharmaceutical producers expand the nomenclature and production volumes, including high -tech drugs. “At the same time, the Russian product is cheaper for the state and consumer, while its quality is high. Everything is quite natural and fits into the overall strategy for ensuring national medicinal security,” he added.
The fact that foreign drugs “go away” are also evidenced by the data of last year.
According to the results of the first seven months of 2023, the range of imported drugs in domestic pharmacies included 6.4 thousand positions. And this is 20.3% less than in January-July 2022.
The main thing is that the domestic product is not only more profitable in price, but is not inferior in quality. And ideally, it should be even better.
